The recent rise of biotech IPOs has been well documented. According to the PitchBook Platform, 2013 saw the most completed biotech IPOs (42) since the turn of the century, only to be outdone by the first half of 2014 (50), which included an outrageous and record-breaking 30 biotech IPOs in 1Q. After the dramatic first quarter, however, the number of completed biotech IPOs has slowed down, dropping to 20 in 2Q and, with two weeks left, sitting at 15 so far this quarter. So, the craze is finally cooling off, right? Not exactly.
12 additional biotechs have filed for initial public offerings this quarter, including Rhythm Pharmaceuticals, Kolltan Pharmaceuticals, Atara Biotherapeutics and Calithera Biosciences, among others. Depending on when they actually go public, the high number of biotech companies currently in IPO registration could produce either a strong finish to this quarter or a fast start to the next one. There's also the possibility that they all go public before quarter's end, in which case 3Q would set the new record for completed biotech IPOs.
Click to explore the data on the PitchBook Platform